🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Two adjacent rooms ECNP right now. Left: "New Frontiers in Psychedelics" (great session btw!) Right: "Best Negative Data Prize in Clinical Neuroscience" Something is very wrong with the system when people just stop caring about what's wrong with the system.

I am thrilled to share our paper on the roles of glycans in HSV-1 infection of skin cells out Nature Communications today. It is dear to my heart having worked on it with the best buddies Copenhagen Center for Glycomics and with help from our friends in Sweden. rdcu.be/dp5gE Hans Wandall #glycotime

Some disasters don't make the news, because they happen every single day. We've become accustomed to these catastrophes, even though they're often (much) worse than even the worst news on the front pages. Case in point: the tobacco industry. /1

Mediedanmark, hjælp mig med at forstå: vi hører jævnligt om politikeres frygt for unge kriminelle på fortove og i kældre. Idag på s 7 i Politiken en notits om, at ungdomskriminaliteten er næsten halveret. HVORFOR ER DET IKKE EN FORSIDENYHED?

The HOME Study (n=2744) 😍 1st RCT of proactive C-L #psychiatry 🤔 No ⬇️ in hospital stay 💪 ⬆️ discharge rate 🧐 ⬇️ mortality 👏 Rated favorably by pts, families, staff 🙌 Largest RCT in hx of C-L psychiatry The question is generalizability (1/3) 🧵 doi.org/10.1016/S2215-…

I’m no oncologist but a) those curves look really similar and b) did I read the OS, correctly, 3.2 months? That’s success? I’m asking.

In our new study in @TheLancetPsychiatry we show that individuals with #schizophrenia requiring #antipsychotic treatments are at increased risk of severe outcomes after respiratory #infections - which could be prevented by targeted vaccinations - moreover we show that #clozapine

US FDA approves first-in-class antipsychotic Cobenfy (previously KarXT) Xanomeline: central M1 & M4 agonist Trospium: non-brain-penetrant, non-selective muscarinic antagonist (to combat peripheral muscarinic effects) FDA: bit.ly/4dpTj2Z Rx info: bit.ly/3XY5zTR